CaP CURE 2002 Review
Contents
From the Chairman 4
From the CEO 6
Year in Review 8
Funding Research 12
Collaboration 22
Raising Money 25
and Awareness
Research Awards 32
Leadership 38
Dr. Ward “Trip” Casscells
Diagnosed with prostate cancer at age 48.
Patient profile on page 10.
William Clapp
Diagnosed with prostate cancer at age 63.
Patient profile on page 20.
Professor Gerald Haslam
Diagnosed with prostate cancer at age 60.
Patient profile on page 30.
Prostate canceraffects everyone,
not just men.Wh en a man gets pro s t a te cancer, it ch a n ge s
his life. And that affects everyone close to him — friends
and family, men and women. That’s why on our cover we
have shown the faces of many people — fathers, mothers,
brothers, sisters, children, physicians, scientists, and others.
They are as committed as we are to finding better treat-
ments and, eventually, a cure.
Family histories and genes may hold
the key to solving part of the prostate
cancer puzzle.
When a man gets prostate cancer, it affects
everyone close to him.
Stu a rt Hol d en ,M . D. , PCF medical dire cto r,
is surrounded by PCF competitive awards
applications.The PCF originated a
“fast-track” grant-application process
so researchers could devote their time to
advancing science rather than pleading
for funds and completing seemingly
endless forms.
Dr. Andrew von Eschenbach, director of
the National Cancer Institute,is the only
cancer survivor ever to hold this office.
Dr. von Eschenbach has contributed to the
PCF’s scientific mission since its inception.
A man is one-third more likelyto get pro s t a te cancer than a woman is to get breast cancer.
Prostate cancer is the most common non-skin
cancer in America, striking 220,000 new men each year.
There is one new case every 2 ½ minutes.
As baby boomer men reach the target zone for
prostate cancer, beginning at age 50, the number of new
cases is projected to increase dramatically. By 2015, there
will be more than 300,000 new prostate cancer cases each
year, a 50% increase.
3
The PCF hosted its 2001 New York Dinner,
a star-studded, fund-raising event at the
Waldorf-Astoria Hotel. Hosted by Whoopi
Goldberg, the dinner honored the Mack
brothers: Bill, David, Earle and Fred.
From left: Debbie Black, Ann Tenenbaum,
Tom Lee, Rupert Murdoch, Whoopi
Goldberg, Joe Torre, Mickey Tarnopol,
Mike Milken and David Foster.
Increasing Public Awareness
Recent scientific advances,
many driven by Prostate Cancer
Foundation-funded researchers,
are more promising than ever.
We changed our name from
CaP CURE to the Prostate Cancer
Foundation to increase public
awareness of our role in harnessing
society’s resources to defeat this
deadly disease.
The need remains great. Your help
has never been more important.
Since 1993, the ProstateCancer Foundation has:
• Raised approximately $200 million.
• Funded more than 1,100 critical
research projects in 100 research
centers around the world.
• Recruited talented scientists.
• Helped to increase annual govern-
ment funding from $25 million to
more than $500 million.
• Greatly increased public awareness,
which encouraged millions more
men to be tested.
• Helped to increase the number
of prostate cancer drugs under
development by 50%.
4
If you’re old enough to remember
the day President Kennedy was
assassinated, you’ll never forget
where you were and what you were
doing. Six years later, you were
prob a bly watching TV and rem em ber
who watched with you when men
first landed on the Moon. More
recently, the tragedy of September
11th is undoubtedly seared in your
memory. And if you, like nearly
one and a half million Americans
each year, ever heard the words
“You have cancer,” you’ll always
remember the moment.
Few families avoid cancer. Thirty-
one years ago, my mother-in-law
learned she had breast cancer. A few
years later, my father was told he
had melanoma. Eventually, this
disease claimed 10 members of my
family. So cancer isn’t something I
think about once in a while — it’s
very immediate, very personal,
and in my thoughts constantly. It
changed the course of my life long
before I was diagn o s ed . It’s one of t h e
reasons my brother and I formalized
our philanthropy in 1982 by estab-
lishing the Milken Family Medical
Foundation with a commitment to
advancing medical research. We
established a program of awards
for young cancer researchers so
they could afford to continue their
laboratory investigations.
Twenty-one years separated my
mother-in-law’s diagnosis from the
day in 1993 when my doctor told me,
“You have prostate cancer.” Over
those two decades, my conversations
with hundreds of doctors — both as
a philanthropist and as a patient
advocate — made me feel about as
well informed as a layman can be on
the complex topic of cancer. So the
shock of learning I had cancer was
compounded by learning how little
information was available about
prostate cancer. Not only was my
prognosis poor — the cancer had
escaped my prostate and was too
advanced for surgery — but informa-
tion about my medical options was
A Passionate Pursuit
Gen. Norman Schwarzkopf joined
Mike Milken in 1998 to address several
hundred th ousand march ers on the Ma ll in
Wa s h i n g ton D. C . at THE MARCH: Coming
Together to Conquer Cancer. Mike and PCF
honorary board member Sydney Kimmel
h el ped orga n i ze the even t . Gen .S chwa r z kop f
is a prostate cancer survivor.
Cancer isn’t something I think
about once in a while — it’s very
immediate, very personal, and
in my thoughts constantly.
5
scarce. In 1993,most experts
thought the prostate cancer death
rate would rise sharply over the
next decade as baby boomers aged.
Yet with little financial support or
public interest, prostate cancer
re s e a rch was con s i dered a back w a ter
of medicine.
The Prostate Cancer Foundation
( form erly CaP CURE) was establ i s h ed
with more in mind than accelerating
a cure for prostate cancer. From the
beginning, we aspired to change
the face of cancer research and to
produ ce re sults that could help peop l e
suffering from a broad range of
serious diseases. We never saw the
process as a zero-sum game where
increased funding for one disease
diminished support for others.
Rather, it has always been one of
our key goals to increase the size of
the research pie in ways that would
ben efit the gre a test nu m ber of peop l e .
The changes that the Prostate
Cancer Foundation has helped
bring about over the past decade are
documented in this Annual Report.
But the most important change is
in the number of prostate cancer
deaths, which have been kept well
below the pessimistic projections of
1993. Also, because of better treat-
ments, survivors enjoy an improved
quality of life. Everyone who has
worked so hard in this effort can
take a large measure of satisfaction
from the results. But despite all that
has been achieved, there’s concern
about the future. Some 70 million
Americans are reaching the age
when the rate of cancers begins to
rise quickly. As Prostate Cancer
Foundation Vice Ch a i rman and
CEO Leslie Mi ch el s on explains
on pages 6– 7,the number of new
prostate cancer diagnoses will soon
grow by as much as 50% if nothing
else changes.
This Annual Report is both a
review of past progress and an
appeal for your involvement in our
continuing effort. The Prostate
Cancer Foundation is the world’s
largest philanthropic source of
support for prostate cancer studies.
We ensure that the scientists
working at the very edge of science
have the resources they need. They
share our sense of urgency, racing
against time to eliminate a disease
that currently takes an American life
every 18 minutes.
We need your support to fast-
forw a rd this qu e s t . I bel i eve ferven t ly
that the goal is attainable when
brilliant, dedicated researchers and
passionate advocates come together
with the ri ght re s o u rce s . We just want
to get there sooner rather than later.
Thank you for helping. Thank you
for expressing your passion for life!
Michael Milken
Founder and Chairman
PCF founder and chairman Mike Milken
(left) and Richard Pazdur, M.D.,director of
the FDA’s division of oncology drug products,
listen to Andrew von Eschenbach,M.D.,
director of the National Cancer Institute
(NCI), during the Prostate Cancer
Foundation’s 2002 Scientific Retreat in
Houston Astros owner Drayton McLane
joined Mike Milken in the fight against
pro s t a te cancer du ring the Pro s t a te Cancer
Foundation’s CaP CURE Home Run
Challenge. Each year, Major League
Baseball,the Major League Baseball
Players Association,the Prostate Cancer
Foundation,and fans nationwide raise
money to fund prostate cancer research
based on home runs hit in 60 ball games
during the week before Father’s Day.
Washington, D.C. Both the Prostate Cancer
Foundation and von Eschenbach advocated
a systems approach to cancer research and
the search for a cure, requiring a close
working relationship between the NCI
and academic and private researchers.
6
The National Cancer Institute’s 2003
projections unfortunately confirm
what our epidemiologists predict.
This ye a r, the nu m ber of n ew pro s t a te
cancer cases in the U.S. will increase
to 220,000. Prostate cancer is now
the most common non-skin cancer
in Am eri c a . It accounts for on e - t h i rd
of a ll major cancers in men — more
than twice the next most common.
One in six men will get cancer in
their lifetime.
It gets worse. As the baby boomer
m en re ach the target age for pro s t a te
cancer, beginning at age 50, the
annual incidence will increase to
300,000 and the annual death rate
will reach 50,000 by 2015. Prostate
cancer is not only distressingly
common; it is also the cancer with
the largest expected increase in the
next decade. Unfortunately, few
people realize the significance of
this disease.
For the past decade, the Prostate
Cancer Foundation has been
working tirelessly to accelerate
the discovery of better treatments
and a cure to prevent this tragedy.
When we began, efforts to find a
cure were at a standstill. Scientists
had few sources of funding and
little reason to engage in prostate
cancer research. Federal funding
was minimal and no ph a rm aceuti c a l
or biotech companies were focused
on it. Men facing prostate cancer
had few good weapons to fight the
disease and little hope that new
treatments would become available
before the disease took its toll.
The Prostate Cancer Foundation
has become the world’s largest
philanthropic source of funding
for prostate cancer research. We
are focused on finding a cure.
With generous support from our
many committed donors, we have
supported some 1,100 research
projects in 100 research centers
around the world since 1993. We
invest 78 cents of every dollar we
raise on medical and scientific
research. That is more than three
times the avera ge amount spent
by the other major health-care
philanthropies.
Letter from the CEO
Age-Specific Probability of Diagnosis of Prostate Cancer
Prostate cancer attacks with remarkable aggression beginning at age 50.
0%
50%
100%
Other Major Disease
Philanthropies
22%
78%
Prostate Cancer
Foundation
Percentage of Funds
Dedicated to Scientific
and Medical Research
7
In the past five years, the number
of prostate cancer drugs under
development has increased 50%.
Federal and corporate funding of
research has increased dramatically
and new experimental strategies
now offer the promise of turning
pro s t a te cancer from a life - t h re a ten i n g
disease into a treatable disorder. We
have been there every step of the
way, prodding government policy
makers to provide more resources,
and ign i ting an ex p l o s i on of s c i en ti f i c
inquiry by researchers in academic
centers, biotechnology firms, and
pharmaceutical companies. We
work closely with these scientists
to accelerate the development of
new treatments.
While we wi ll con ti nue our histori c a l
efforts, now we must also:
• Identify and act on specific oppor-
tunities to accelerate the biomedical
research and development process
in prostate cancer;
• Im prove the ef f i c i ency and ef fec-
tiven e s s of work funded by others;
• Infuse the entire system with a
greater sense of urgency and
accountability; and
• Increase our support for bold,
high-impact initiatives.
We face special challenges in our
effort to harness more of society’s
resources to fight prostate cancer,
however. First and foremost,there
is little public recognition of the
gravity of this disease. Few people
realize that a man is one-third more
likely to get prostate cancer than a
woman is to get breast cancer.
Second, this disease attacks men,
a tough group to get motivated to
prevent a future health problem.
Many men characteristically refuse
to confront health issues until they
are compelled to do so and are
particularly reluctant to deal with
sensitive issues related to sexual
health. To address these challenges,
we are launching communications
and other programs to raise public
awareness and educate men and
their families.
Although the progress in finding
better treatments has been dramatic,
the impending increase in incidence
makes the need greater than ever.
Fortunately, recent advances in
science have made the opportunities
greater than ever as well. With your
support, we will be able to pursue
more of these opportunities and
hasten the day when prostate cancer
is merely a sad memory.
Leslie D. Michelson
Vice Chairman and CEO
New Cancer Cases (in thousands)
Prostate cancer is the most common and most rapidly increasing cancer.
8
Prostate Cancer Foundation
Year in Review
PCF volunteers Ferne Milken, Sybil Gordon
and Elly Levin proudly wear their “CURE”
hats while putting together information
packets about prostate cancer. PCF board member Mickey Tarnopol
and his wife, Lynne, were the benefit co-
chairs for the 2001 New York Dinner at
the Waldorf-Astoria Hotel in New York.
The Tarnopols helped make the PCF
dinner a great success.
Members of the PCF Therapy Consortium
meet regularly to address major issues that
impede progress in clinical development of
new treatments.The Therapy Consortium
comprises eight centers of excellence where
leading medical oncol o gists wo rk on improved
prostate cancer treatments.
Since its inception in 1993, the
Prostate Cancer Foundation (PCF) has become a model for
other philanthropies, simplifying and speeding the grant-
application process, organizing centers of excellence, bringing
toget h er ex pertise from all corn ers of the scien tific com mu n i ty,
and encouraging close collaboration among research leaders.
The PCF has helped to nurture the best talent in medical
research institutions around the world and broken down
b a rri ers bet ween the labora tory and the cl i n i c , h elping pati en t s
receive state-of-the-art treatments sooner. Our efforts have
contributed to a 50% increase in the number of prostate
cancer drugs under development in the past five years and a
20-fold increase in government funding of prostate cancer
research over the past 10 years.
9
Since 1996,the PCF has partnered with
Major League Baseball and the Major
League Baseball Players Association in the
Prostate Cancer Foundation CaP CURE
Home Run Challenge. With support from
Major League teams, coaches, players,
managers and umpires,the HRC has
ra i sed more than $18 million for pro s t a te
cancer research.
Safeway, one of the largest food retailers in
North America, partnered with the PCF
for a third year in a row to raise money
and awareness. Steve Burd,Safeway’s
president and chief executive officer, led a
company-wide campaign that include d
po i n t - of - pu rch a se pro m otions at more than
The Prostate Cancer Foundation is
the world’s largest philanthropy
supporting prostate cancer research.
The PCF has earned wide-
spread respect by:
• Attracting and aggregating a
critical mass of talented and
dedicated scientists conducting
basic and translational research;
• Creating a rapid-response, risk-
taking funding system that reduces
bureaucracy and accelerates research
while maintaining scientific rigor;
• Raising awareness of the need
for more prostate cancer research
funding by government agencies
that have increased appropriations
from roughly $25 million in 1993
to more than $500 million today;
• Forming a Therapy Consortium
of eight leading prostate cancer
research centers;
• Creating the largest database of
f a m i ly - clu s tered pro s t a te cancer cases;
• Creating a tissue bank and animal
model network; and
• Fostering collaboration among aca-
demic, corporate, and governmental
researchers through the annual PCF
Scientific Retreat and other forums.
15,000 checkout stands in all 1,600
Safeway stores in the U.S. Employees
also participated in internal fundraising
drives to boost proceeds. In 2003, the
campaign raised more than $2.5 million
for prostate cancer research.
10
Dr. Ward “Trip” Casscells
Diagnosed with prostate
cancer at age 48.
Dr. Ward “Trip” Casscells, an inter-
nationally recognized cardiologist,
has spent his career developing
better treatments for and helping
patients survive heart disease.
One night in 2001,he woke with an
unusual pain in his stomach. Lying
in bed, he examined his abdomen
and was stu n n ed to find an abn orm a l
growth.Days later, an MRI revealed
metastatic prostate cancer. His prog-
nosis: 18 months to live. He was 48,
at the peak of a successful medical
career, a husband and the father o f
three young children.“I wanted to
scream or cry, but I didn’t have
time,” Dr. Casscells remembers.“I
envisioned writing letters to my
children and making a videotape
for them to remember me. It was
overwhelming.”
Dr. Casscells immersed himself in
the available state-of-the-art treat-
ments for his condition. He and his
wi fe , Rox a n n e ,s aw Drs . Ch ri s toph er
Logothetis,a medical oncologist,
and Andrew von Eschenbach, a
urologist who has become director
of the National Cancer Institute, at
M. D. Anderson Cancer Center.
“We’ ll get you fixed up,” D r. Logo t h eti s
said. He prescribed an innovative
and aggressive regimen of hormones
and chemotherapy intended to treat
advanced prostate cancer. After just
one day, Dr. Casscells felt better.
“When the Prostate Cancer
Foundation funded the develop-
ment of this treatment program,
chemotherapy for prostate cancer
was regarded as a poison unfit for
humankind,” says Dr. Logothetis.
As recently as three years ago, Dr.
Casscells’ only option would have
been single therapy with hormones
and the prognosis would have been
• Prostate cancer is the most com-
mon non-skin cancer in America,
striking 220,000 men in 2003.
• Prostate cancer attacks aggressively
beginning at age 50.
• The number of new cases per year
is projected to increase by 50% to
300,000 by 2015.
gri m .P C F- f u n ded re s e a rch progra m s
like this have shown that integrated
treatment approaches can help
keep prostate cancer at bay for years.
Oncologists are learning to use these
revo luti on a ry therapies wi s ely, g u i ded
by biochemical markers that help
monitor their effectiveness.
The markers are “predictive of
relapse, and can guide the selection
of f utu re thera py,” s ays Dr. Logo t h eti s .
“When we needed funding to initi-
ate this research, only the PCF was
willing to step forward.”
Since completing this combination
of chemotherapy and hormones
two years ago, Dr. Casscells’ disease
remains in remission. Today, he
foresees a longer future and hopes
to see his children graduate from
high school and reach other mile-
stones. He hasn’t sat down yet to
write anything to them.“I’ve been
given my life back,” he says.“I don’t
know how the story turns out.”
He was 48,at the peak of a successful
medical career, a husband and the father
of three young children.“I envisioned
writing letters to my children and making
a videotape for them to remember me.
It was overwhelming.”
Patient Profile
“I wanted toscream or cry, but I
didn’t have time.”
12
• Funded the development of vaccines
that harness the body’s immune
s ys tem to kill pro s t a te cancer cell s ;a n d
• Funded gene therapy approaches
to selectively eliminate prostate
cancer cells.
PCF grant funding has led directly
to many adva n ces in com preh en d i n g
the underlying mechanisms of
prostate cancer — advances that
have or will lead to better treat-
ments of prostate cancer:
• Identification of the genetic changes
that might cause cells in the prostate
to become cancerous;
• Stopping the production or func-
tion of growth factors that cancer
cells need to continue growing;
• Interfering with the development of
blood vessels that feed nutrients to
cancer cells;
• Determination of the structure of
the androgen receptor, the molecule
that drives the growth of prostate
cells,and the discovery of ways to
inhibit it;
The PCF Funds High-
Potential Research
Just as venture capital firms advance
technology by funding promising
commercial strategies and products,
the Prostate Cancer Foundation
fo ll ows a similar model by su pporti n g
innovative,early-stage research
projects that offer the greatest hope.
These high - i m p act re s e a rch proj ect s ,
many of which would not have
been funded without our support,
include clinical research to evaluate
new drugs,innovative treatment
strategies for prostate cancer, and
basic science research to understand
the biology of prostate cancer. As
part of its efforts to move drugs into
the clinic quickly, the PCF has:
• Funded the discovery and/or early
clinical devel opm ent of PSMA mon o-
clonal antibodies, Velcade, Zometa,
Atrasentan,and Omnitarg;
Funding Research
The PCF has funded more than
1,100 crucial research projects
in 100 research centers around
the world.
Alaska Senator Ted Stevens,a cancer
survivor and chairman of the U.S. S en a te
Appropri a tions Co m m i t te e , has be en one of
the earliest su ppo rters of the PCF and its
mission to find better treatments and a
cure for prostate cancer. Senator Stevens
has been one of the strongest congressional
advocates for increased cancer funding.
All 30 Major League Baseball teams provide
support for the Prostate Cancer Foundation
CaP CURE Home Run Challenge in many
ways.Clubs host pre-game ceremonies, run
pu blic servi ce annou n cem en t s ,d o n a te ti cket s ,
place blue ribbons on the field and support
the player representatives. Owners, coaches,
executives,umpires, trainers, groundskeepers,
and front office staff are behind the cause by
h o s ting spe cial events en d o rsing and pro m oti n g
the Home Run Challenge.
13
• Identification of prostate cell surface
markers that can be targeted to
destroy cancerous cells; and
• Development of analytical methods
that identify the proteins in blood
or the prostate that correlate to
treatment effect or behavior of the
cancer cell — also known as
proteomic pattern recognition.
Competitive Awards
The PCF originated a “fast-track”
grant-application process so
researchers could devote their time
to advancing science rather than
pleading for funds and completing
seemingly endless forms. The time
from submission of a request to
money-in-hand was reduced to 90
days. The reporting of results was
reduced to a six-month progress
report letter and a presentation at
the annual PCF Scientific Retreat.
PCF competitive research awards
have resulted in a dramatic increase
in the number of talented physicians
Mike Milken and Baseball Hall of Fame
manager Tommy Lasorda look on as News
Corp. chairman Rupert Murdoch,a prostate
cancer survivor, leads a “wave” at Dodger
Stadium to celebrate another home run that
raised money for prostate cancer research
during the Prostate Cancer Foundation
CaP CURE Home Run Challenge.
(Photo courtesy of the Los Angeles Times)
Bob Dole, former Senate Majority Leader
and presidential candidate, told attendees
at the 2002 PCF Sci en tific Retreat about his
experience as a prostate cancer survivor.
Nobel laureates in medicine and science
debated our biological and scientific
future at the 2003 Milken Institute Global
Co n feren ce . From left: Syd n ey Bren n er, wh o
received his Nobel Prize for his discoveries
concerning genetic regulation of organ
development and programmed cell death;
Steven Chu, who received his Nobel Prize
for the development of methods to cool and
trap atoms with laser light; Mike Milken,
chairman and founder of the PCF and the
Milken Institute; and Joshua Lederberg,
who received his Nobel Prize for discoveries
concerning genetic recombination.
and scientists who are conducting
prostate cancer research. In order
to attract new talent, nearly half of
these PCF-funded awards are earned
by qualified researchers who have
never before received PCF funds.
Leaps of Faith Lead to
Meaningful Results
The impact of PCF-funded
programs is realized when they
demonstrate great promise and
receive funding from bi o tech n o l ogy
and ph a rm aceutical companies
or from government research
a gen c i e s . Examples of PCF su cce s s
stories include:
Velcade Chemist Julian Adams had
lost internal support at his company
for ongoing research on a com-
pound named PS-341 (Velcade)
and the project was about to b e
terminated. He persuaded the PCF
to fund a Phase I clinical trial of
Velcade. The results of this study
were encouraging. As a result,
Millennium Pharmaceuticals, a
The PCF cuts through the red
tape of research funding. PCF
grant applicants are limited to
five-page submissions and get a
response within 60 days… with
funds delivered in 90 days.
14
major biotech firm, acquired the
company that owned Velcade and
invested millions of dollars to
continue development of the drug.
In 2003, the FDA approved Velcade
for the treatment of multiple
myeloma — a cancer of the blood.
There is significant interest in com-
bining Velcade with chemotherapy
for advanced prostate cancer and
s tudies of this tre a tm ent com bi n a ti on
are currently in progress. Further
studies in advanced prostate cancer
and other solid tumors continue.
Zometa The PCF funded medical
oncologist Matthew Smith, M.D.,
Ph.D., of Massachusetts General
Hospital to conduct a series of
clinical studies at Harvard Medical
School on the use of bisphospho-
nates in the treatment of advanced
prostate cancer. The first clinical
trial con du cted by Dr. Smith foc u s ed
on the use of a bisphosphonate
known as Aredia (pamidronate)
for the prevention of bone loss
in patients undergoing androgen
deprivation therapy (ADT).
An estimated one million men
diagnosed with prostate cancer are
undergoing ADT with loss of bone
density (osteoporosis) as a major
side effect. The results of this study
were published in the New England
Journal of Medicine in September
2001 and showed that Aredia mini-
mizes bone loss and associated
skeletal-related events in men
undergoing ADT.
Based on these encouraging results,
Novartis,the seventh largest phar-
maceutical company in the world
and the manufacturer of Aredia,
committed significant resources to
the development of a more potent
bisphosphonate known as Zometa
(zolendronate) to prevent bone loss
and skeletal-related events in men
with pro s t a te cancer under going A D T.
PCF-funded research results
in effective treatments to
patients living with advanced
prostate cancer.
Leroy Hood,M.D., Ph.D., president,director
and professor at the Institute for Systems
Biology, was the architect of the PCF Gene
and Family Studies Consortium, which
has created the largest repository of genetic
samples from families with multiple indi vid-
uals affected by prostate cancer. The goal of
the consortium is to identify genes that cause
prostate cancer.
Home Run Challenge Goodwill Ambassador
and Baseball Hall of Fame manager, Tommy
Lasorda,stands between New York Yankees
manager Joe Torre (left),a prostate cancer
survivor and New York Yankees bench coach
Don Zimmer in Joe Torre’s office before a
Prostate Cancer Foundation CaP CURE
Home Run Challenge game.
Stewart Resnick and his wife, Lynda, a
PCF board member, have long been major
supporters of medical research and other
charities.They joined “Magicians of the
Century” Siegfried and Roy at a 2002 e vent
that raised several million dollars for PCF-
funded research.
Funding Research
15
In 2001, Novartis gained FDA
approval for Zometa for the treat-
ment of prostate cancer and other
solid tumors in bone.
Atrasentan In the early 1990s, a
drug called Atrasentan (formerly
designated ABT-627) was being
developed by Abbott Laboratories,
one of the largest pharmaceutical
companies in the world, to treat
cardiovascular disease. The drug
blocks the activity of a molecule
called endothelin that closes blood
vessels.A team of scientists at The
Johns Hopkins University discov-
ered that endothelin also caused
prostate cancer cells to grow. They
applied to the PCF for funds to test
Atrasentan.PCF-funded research
demonstrated that Atrasentan
slowed prostate cancer growth in
test tubes and in animal models.
Based on these results, Abbott
Laboratories has committed
hundreds of millions of dollars
The PCF:
We cut red tape.
We get results.
We provide hope.
Celestia Higano, a medical oncologist at the
University of Washington,describes results
from a recent clinical trial of a new drug for
advanced prostate cancer to PCF chairman
and founder Mike Milken at the 2001 PCF
Scientific Retreat at Lake Tahoe.
Gary Becker, Nobel laureate in economics,
spoke at the 2002 PCF Scientific Retreat.
Becker, considered one of the world’s leading
economists,has helped the PCF direct strate-
gies in research funding. Recognized for his
expertise in human capital,economics of the
family, and economic analysis of crime,
discrimination and population, Becker is a
prostate cancer survivor.
to the ongoing development of
Atrasentan to treat prostate cancer.
The drug is now in Phase III clinical
trials to determine wh et h er Atra s en t a n
can inhibit the growth of prostate
cancer cells in bone, relieve pain,
and improve quality of life for those
patients living with prostate cancer.
PCF participation was crucial to The
Johns Hopkins investigators because
funding for these types of “out-of-
the-box”studies is nearly impossible
to obtain. Without PCF funding
of this high-potential research,
Atrasentan may have never been
developed to treat prostate cancer.
Omnitarg Dr. David Agus, a medical
oncologist at Cedars-Sinai Health
Science Center in Los Angeles, was
formerly studying leukemia and
lymphoma at Memorial Sloan-
Kettering Cancer Center (MSKCC)
in New York.Scientists at MSKCC
rec ru i ted Dr. Agus to begin labora tory
16
studies to characterize new drug
candidates for prostate cancer. One
su ch dru g, produ ced by bi o tech-
n o l ogy company Genentech and
known as Omnitarg (formerly 2C4),
was studied by Dr. Agus and was
determined to be a potential treat-
ment for human prostate cancer.
Upon relocation to the Warschaw
Prostate Cancer Center at Cedars-
Sinai, a member of the PCF Therapy
Consortium,Dr. Agus was funded
to furt h er devel op Omnitarg. Arm ed
with these preclinical results in
prostate cancer, the PCF persuaded
G en en tech , a bi o tech n o l ogy com p a ny,
to conduct further development of
this drug candidate with pro s t a te
c a n cer as the lead indicati on .
This represents great progress
because most drugs are initial ly
tested in other cancers because of
the special challenges in evaluating
ef f i c acy in pro s t a te cancer. The
devel opm en t of Omnitarg is a
model case for the positive influence
of the PCF on pharmaceutical
companies to invest in prostate
cancer drug development.
PSMA Monoclonal Antibodies
Frequently, drugs developed by
PCF-funded investigators produce
treatments for many types of cancer.
PCF-funded research conducted
by Dr. Neil Bander at Cornell
University Medical School in New
York focuses on the use of a mono-
clonal antibody against Prostate-
Specific Membrane Antigen
(PSMA), a molecule found on
the surface of prostate cancer cells.
Monoclonal antibodies are proteins
engineered in the laboratory to bind
specifically and potently to a single
molecule. Intravenous injections
of monoclonal antibodies against
PSMA have been demonstrated to
concentrate at sites of prostate
cancer. This shows that they can
be used to deliver lethal doses of
Drugs developed by PCF-funded
investigators produce treatments
for all types of cancer.
Dr. Jonathan Simons, a medical oncologist
and Cancer Center director at Emory
University, is a PCF-funded physician/
sci en ti s t . Dr. Simons has made sign i f i c a n t
contributions in the area of prostate
cancer vaccines.
Intel chairman and PCF board memb er
Andrew Grove has helped accelerate the
pa ce of m edical re se a rch by sharing bu s i n e s s
principles that have led to success in the
high-tech industry. Dr. Grove is also a
prostate cancer survivor.
Funding Research
17
The PCF has significantly acceler-
ated the pace of discovery and
development of the most promising
prostate cancer treatments.
In 2001,the PCF sponsored a run/walk to
raise prostate cancer awareness. More than
5,000 men, women,and children assembled
at the Los Angeles Staples Center for the
Champions Challenge for a Cure.
Christopher Logothetis,M.D., chairman
of genitourinary medical oncology at the
University of Texas M. D. Anderson Cancer
Center, is at the forefront of clinical research
on prostate cancer. Dr. Logothetis was a
founding member of the Prostate Cancer
Foundation Therapy Consortium. At the
2002 PCF Scientific Retreat in Washington,
D.C.,he presented the results of his research
on specific gene-therapy approaches to
prostate cancer.
radiation or toxins directly to
prostate cancer, eradicating or
reducing the tumor.
Subsequent work showed that this
approach had even greater potential.
PSMA molecules, which had been
thought to exist only in prostate
cancer cells, were discovered on the
surface of cells lining new blood
vessels that feed many tumors in
addition to prostate cancer. This
suggested a potentially broad thera-
peutic activity of PSMA monoclonal
antibodies for breast, lung, and
colon cancers, in addition to
prostate cancer.
Realizing the potential of this new
treatment, biotechnology company
Millennium Pharmaceuticals is
currently funding the clinical devel-
opment of this PSMA monoclonal
a n ti body not on ly for pro s t a te cancer,
but potentially for other cancers as
well . At least two other ph a rm aceuti c a l
companies, Progenics and Medarex,
are developing their own PSMA
monoclonal antibodies specifically
for the treatment of prostate cancer.
These novel therapies illustrate
the progress being made. The hard
work of PCF-supported researchers
over the past 10 years is producing
therapies that are entering the
clinical-trial stage at an increased
rate. This provides hope for men
already living with prostate cancer,
as well as the approx i m a tely 220,000
men who will be diagnosed with
prostate cancer in 2003.
18
Increased Government Fu n d i n g
The Prostate Cancer Foundation
has been a strong and successful
advoc a te for incre a s ed govern m en t
funding for pro s t a te cancer
research. Since 1993, the PCF has
raised awareness that has helped
to i n c rease annual govern m ent
funding earmarked for prostate
cancer from $25 million to more
than $500 million. The increased
funding of prostate cancer research,
and cancer research in general,
has resulted in a major increase in
treatment programs.
National Cancer Institute
The PCF encouraged the National
Cancer Institute to expand its
Specialized Program of Research
Excellence program that helps to
accelerate the pace of development
of some of the most promising
prostate cancer drugs.
Since 1993, the PCF has raised
awareness that has helped to
increase annual government
funding earmarked for prostate
cancer from $25 million to
more than $500 million —
a 20-fold increase.
Specialized Program of
Research Excellence
The Specialized Program of
Research Excellence (SPORE)
encourages translational science
that spans the gap between basic
research and clinical applications.
The first two prostate cancer
SPOREs were funded in 1992
and increased to three in 1995.
Today, there are 11 prostate cancer
SPOREs with a total annual budget
of approximately $27 million.
The Department of
Defense Prostate Cancer
Research Program
In 1996, the PCF worked closely
with the National Prostate Cancer
Coalition and successfully urged
Congress to provide Department
of Defense funds specifically for
prostate cancer research under a
new mandate, the Prostate Cancer
International financier Thomas H. Lee
(left) attended the PCF Shadow Creek
Invitational along with Jerry West (center),
one of the 50 greatest players in NBA
history, and Dr. Howard Scher, a PCF-
funded investigator at Memorial Sloan-
Kettering Cancer Center in New York,an
internationally recognized investigator in
the field of genitourinary cancers.
The PCF supports physician/scientists at the
forefront of translational research.These
scientists advance drugs from the laboratory
bench to the patient ’s bedside. Translational
research scientists are one of the most impor-
tant catalysts for the development of new
therapies for advanced prostate cancer.
PCF boa rd mem ber David Ko ch and his wi fe ,
Ju l i a ,h ave long be en gen erous su ppo rters of
medical research and other charities.This
year, the PCF launched the D avid H. Koch
Awards.Mr. Koch’s extraordinary generosity
enabled the PCF to provide more than
$3 million to fund major research programs.
Funding Research
19
The Donald J. Trump Pro/Am Tennis
Invitational at the Mar-a-Lago Club in
Palm Be a ch has ra i sed more than $5 mill i o n
for prostate cancer research since the
program began in 1998.
Safeway joined the PCF in the fight against
prostate cancer with two longbed trucks that
travel throughout Northern and Southern
California. As part of a fund-raising effort
each year during the month of June,Safeway
and Vons customers made donations to the
PCF’s cancer-fighting efforts at chec kout
cou n ters .S a feway em pl oyees also pa rti ci pa ted
in a corporate donation drive.
Research Program (PCRP).
The PCRP’s mission promotes
innovative, multi-institutional,
multidisciplinary research aimed
at eradicating prostate cancer.
To date,the PCRP has provided
$395 million and has funded 797
peer-reviewed projects in response
to congressional appropriations.
The PCRP has become the secon d
l a r gest funder of prostate cancer
research in the United States.
This increase in federal support
has created a large and stable source
of funding needed to continue the
development of new drugs discov-
ered by PCF-funded research and
has attracted a critical mass of
scientists contributing to the
prostate cancer field.
As a result of the Prostate Cancer
Foundation’s advocacy, California
now requires that health insur-
ance companies and Medi-Cal
pay for routine treatment costs
incurred by cancer patients in
clinical trials.
20
William Clapp
Diagnosed with prostate
cancer at age 63.
When he changed doctors at age
63, William Clapp received his first
prostate specific antigen (PSA) test.
The results showed that he probably
had metastatic prostate cancer.
This simple blood test detects
the amount of prostate specific
antigens in the blood. The higher
the reading, the greater the likeli-
hood of prostate cancer.
Medical authorities recommend
that all men have annual PSA tests
beginning at age 50 (or age 40 for
African American men or those
with a family history of prostate
cancer since they are at higher risk).
Nonetheless, Mr. Clapp’s prior
physician had neglected to conduct
a PSA test.
Mr. Clapp’s own test results
prompted him to research the
disease thoroughly. “The more I
• Black men have the highest
incidence of prostate cancer in
the world.
• Compared to Caucasian men, they
are 1.5 times more likely to get
prostate cancer and 2.3 times more
likely to die from prostate cancer.
• Prostate cancer has the strongest
familial link of all major cancers.
learned,” he says, “the more afraid
I was of dying.” Mr. Clapp elected
to be treated by Dr. Philip Kantoff,
a Pro s t a te Ca n cer Fo u n d a ti on-
supported oncologist who heads
the Lank Center for Genitourinary
Oncology of the Dana-Farber
Ca n cer In s ti tute at Ha rva rd Med i c a l
School. Mr. Clapp participated in
a PCF-funded study that uses
chemotherapy before surgery.
Men such as William Clapp, with
very high PSA levels, are typically
poor candidates for surgery because
their disease often has spread to
other organs. “They receive hor-
mones plus radiation, and then you
just cross your fingers,” Dr. Kantoff
says. Because Mr. Clapp’s prostate
cancer appeared to be confined,
surgery was a possibility, especially
with the use of chemotherapy
before surgery.
Although the chemotherapy made
the difference between success and
failure, Dr. Kantoff says, “The story
here is the whole approach of
trying drugs preoperatively, which
is very labor- i n ten s ive and ex pen s ive
and would not have been possible
without the PCF’s vision and
funding.” Without it,Mr. Clapp
might have been written off as a
h opeless case. In s te ad , he has don e
extraordinarily well.
Mr. Clapp continued to work
during chemotherapy and missed
only a month of work after surgery.
Then, in May 2002,at age 65,he
retired. Now he spends his days
working out at a YMCA, taking
culinary arts classes, and playing
with his young grandsons. His PSA
has remained at zero for the past
two years. And he can look forward
once again.
His whole perspective on life has
changed.“I’m more calm now,
because there are more important
things in life.I want to live longer
than my grandfather, who died at
93.I think I can do it. I feel like I’m
born again.”
Family histories and genes may hold the
key to solving part of the prostate cancer
puzzle.The PCF Gene and Family Studies
Consortium created the largest repository of
genetic samples from families with multiple
individuals affected by prostate cancer. The
consortium partnered with academic experts
to discover cancer-related genes and targets
that can lead to new medications.
Patient Profile
“The moreI learned, the more afraid
I was of dying.”
22
The Prostate Cancer Foundation
has created and supported a series
of networks and consortia among
academic research scientists,
bi o tech n o l ogy and ph a rm aceuti c a l
com p a n i e s , govern m ent re s e a rch ers ,
and grassroots organizations
to maximize collaboration and
idea exchange. All PCF-funded
researchers are required to share
their findings with colleagues
around the globe and participate
actively with other research leaders.
Therapy Consortium
The PCF has assembled a team of
medical oncologists at eight leading
U.S. cancer centers that specialize
in prostate cancer research. The
m em bers of this Th era py Con s ortiu m
meet regularly to address major
i s sues that impede progress in cl i n i c a l
development of new treatments.
The Prostate Cancer Foundation
Research Therapy Consortium
in 2002:
• M. D. Anderson Cancer Center
• The Johns Hopkins University
• University of California,
San Francisco
• Memorial Sloan-Kettering
Cancer Center
• Cedars-Sinai Prostate Cancer Center
• University of Wisconsin
• University of Michigan
• Dana-Farber Cancer Institute,
Harvard Medical School
Members test each other’s ideas;
co ll a bora te in de s i gn i n g, con du cti n g,
and evaluating clinical trials, many
of which were funded by the PCF;
and develop new drugs and treat-
ments. Major contributions and
activities of the group include:
Collaboration
The PCF has assembled a
team of medical oncologists
at eight leading U.S. cancer
centers that specialize in
prostate cancer research.
A routine physical in 1997 brought the news
to professional golfer Jim Colbert that he had
prostate cancer. Now he’s joining golf legend
and fellow prostate cancer survivor Arnold
Palmer in a partnership between the
Champions Tour and the PCF to rais e
funds for prostate cancer research.
Donald S. Coffey, Ph.D. (left), considered the
“f a t h er of pro s t a te cancer re se a rch ,” is profe s so r
of urology, oncology and pharmacology and
molecular sciences at The Johns Hopkins
Un ivers i ty. Dr. Cof fey disc u s sed the PCF’s 10
years of progress with PCF medical director,
Stuart Holden,M.D. (right),and Leslie D.
Michelson,PCF vice chairman and C E O,
at the PCF Ninth annual Sci en tific Retre a t .
23
• Establishing taxane-based
ch em o t h era py as a tre a tm ent opti on
for advanced prostate cancer;
• Acting as a planning group to initi a te
new academic and industrial trials
for prostate cancer treatments;
• Screening new drugs for inclusion
in trials;
• Participating in clinical-trial
standardization programs; and
• Working together to select a clinical
research informatics system to link
the participating centers.
Scientific Retreat
The Prostate Cancer Foundation
Scientific Retreat has become one
of the most prominent annual
m edical events in the nati on ,d rawing
hundreds of pioneering scientists
and physicians, government leaders,
prostate cancer advocates,and
bi o tech and ph a rm aceutical com p a ny
executives. For three intensive days,
these leaders address scientific
advances, present ongoing research,
deb a te topical issues rel a ted to pro s t a te
cancer, and examine better ways to
fund research and produce results.
The 2002 Prostate Cancer
Foundation Scientific Retreat was
h eld in Wa s h i n g ton , D. C . to high l i gh t
the import a n ce of the govern m en t’s
role in our efforts. Dr. Andrew von
Eschenbach, newly appointed by
President Bush as director of the
Na ti onal Ca n cer In s ti tute and a
pro s t a te cancer su rvivor, s po ke
eloquently of the Prostate Cancer
Fo u n d a ti on’s ef fectiveness in “get ti n g
done the things that need to be don e .”
The PCF selects and provides
funding for high-impact
projects capable of producing
cutting-edge results by some
of the world’s most forward-
thinking scientists.
Businessman Carl Lindner (left), owner
of the Cincinnati Reds and Honorary PCF
board member, has been an avid and
generous supporter of the Prostate Cancer
Fou n d a tion CaP CURE Home Run Chall en ge .
Several hundred thousand people from more
than 600 cancer groups across America met
on the Washington Mall in 1998 for THE
MARCH: Coming Together to Cure Cancer.
THE MARCH helped raise awareness of
cancer issues on Capitol Hill and preceded
a major increase in government funding of
prostate cancer research.
24
The Prostate Cancer
Foundation in Israel
The Prostate Cancer Foundation
began funding research programs
in Israel three years ago. Since
inception, nearly $4.7 million has
been provided to 59 programs.
The PCF has achieved many of the
objectives in Israel that have been
benchmarks of PCF activities in
the U.S. Specifically, the PCF has
recruited the best and brightest to
the field, initiated venture programs,
and fac i l i t a ted significant net work i n g
among scientists from many
Israeli institutions. In addition,
the PCF initiated a Centers of
Excellence program that requires
multiple centers to join in a single
proposal with significant impact on
the science of prostate cancer. In
2002, the PCF funded a Centers of
Excellence award that joined the
Technion Institute,the Weizmann
Institute,and Hadassah University
Hospital. This multidisciplinary
program has the po ten tial to gen era te
new drug t a r gets for the tre a tm ent of
rec u rren t prostate cancer.
This program is the PCF’s first step
in linking scientific leaders from
around the world in an intensified
effort to find better treatments and
a cure for prostate cancer.
Partnering with Industry
Moving a treatment from lab to
market can take as long as 12 years.
For the Prostate Cancer Foundation,
that is simply too slow. That is
why the PCF works closely with
biotechnology and pharmaceutical
companies to get re s e a rch innova ti on s
to patients faster.
PCF funding has all owed inve s ti ga tors
to accelerate the pace of develop-
m ent of the most promising pro s t a te
cancer treatments by:
• Funding the underlying science that
led to the treatment being studied;
• Funding early clinical trials; and
• Encouraging and assisting
the company.
Cincinnati Reds outfielder Ken Griffey Jr.
is a Prostate Cancer Foundation CaP CURE
Home Run Challenge featured star represen-
tative. With such awesome power supporting
the 2003 Home Run Chall en ge , it was anot h er
groundbreaking year for the PCF in its
mission to find better treatments and a cure
for prostate cancer.
Steve Burd (left), Safeway president
and CEO, introduces Prostate Cancer
Foundation chairman Mike Milken at
Safeway’s kickoff to its month-long
campaign to raise money for prostate
cancer research.
Collaboration
PCF chairman Mike Milken (second from
right) stands with some of the PCF’s biggest
Home Run Challenge supporters. From left:
Former A’s and Twins catcher and founding
Home Run Challenge co-chair Terry
Stei n ba ch and Ba l ti m o re Ori oles minori ty
owners Bill Beatson Jr. and Steve Geppi.
The Prostate Cancer Foundation
and the investigators it funds
work closely with many pharma-
ceutical and biotech companies
including: Abbott Laboratories,
Bayer, Cell Genesys, Genentech,
G l a x o S m i t h Kline, Medarex, Merck,
Millennium Pharmaceuticals,
Novartis, and Pfizer.
25
Since 1996, the PCF has part-
nered with Major League Baseball
and the Major League Baseball
Players Association to raise more
than $18 million for prostate
cancer research.
Lowell Milken (left) with PCF medical
director Stuart Holden,M.D. (far right)
at the 2001 PCF Scientific Retreat held at
Lake Tahoe, Nevada. Lowell Milken,
co - fou n d er of the Mi l ken Fa m i ly Fou n d a ti o n ,
has been one of the top supporters of the
PCF since its inception in 1993.
The Prostate Cancer Foundation
conducts many programs aimed at
raising not only research f u n d i n g
but also public aw a reness of the
significance of prostate cancer.
The Prostate Cancer
Foundation CaP CURE
Home Run Challenge
Since 1996, the PCF has partnered
with Major League Baseball and
the Major League Baseball Players
As s oc i a ti on to raise more than
$18 mill i on for pro s t a te cancer
re s e a rch . E ach Ju n e , fans pled ge
anywhere from 25 cents to $10,000
for every home run hit in 60 sel ected
games the week before Father’s Day.
All 30 Major League Baseball teams
provide support for the Home
Run Challenge in many ways. Clubs
host pregame ceremonies, run pub-
lic s ervi ce announcem en t s , don a te
ti cket s , place blue ribbons on
the field,and support the player
repre s en t a tive s . In ad d i ti on ,a ll Ma j or
League managers, such as Joe Torre
of the New York Yankees and Dusty
Baker of the Chicago Cubs, both
prostate cancer survivors, also par-
ti c i p a te . Own ers , exec utive s , coach e s ,
umpires, trainers, groundskeepers,
and front office staff are behind
the cause by hosting sp ecial events
en dorsing and prom o ting the Hom e
Run Challenge.
Safeway and the Prostate
Cancer Foundation
Safeway, one of the largest food
ret a i l ers in North Am eri c a ,p a rtn ered
with the PCF for a third year in a
row to raise money and awareness.
Steve Burd, Safeway’s president and
ch i ef exec utive of f i cer, l ed a com p a ny -
wide campaign that included
Raising Money
and Awareness
26
point-of-purchase promotions at
more than 15,000 checkout stands
in all 1,600 Sa few ay stores in the U. S .
Employees also participated in
i n ternal fund-raising drives to boo s t
proceeds. In 2003, the campaign
raised more than $2.5 million for
prostate cancer research.
Champions Tour for the Cure
Led by golf legends and prostate
cancer survivors Arnold Palmer, Jim
Co l bert , Bobby Wa l zel , and Ray Floyd ,
this program focuses on fans of the
Champions Tour. Supporters pledge
$1 or more for each birdie made by
their favorite player(s) during the
s e a s on . Every bi rdie made bet ween the
MasterCard Championship in late
January through the season-ending
Champions Tour Championship
at Gaillardia in October supports
prostate cancer research.
Arnie’s Army
Named for honorary chair Arnold
Palmer, this program involves
p a rti c i p a ting go l f co u rses spon s ori n g
one-day, closest-to-the-pin contests
on a pre s el ected par-3 hole. Ba n n ers ,
tee markers, pin flags, and other
collateral materials carry the
program logo and all golfers are
encouraged to join Arnie’s Army
to raise funds and generate public
awareness of prostate cancer.
In 2002, the Prostate Cancer
Foundation began the program
in the North Florida section of the
PGA. This year, Arnie’s Army moves
across the nation with the goal of
enlisting hundreds of golf courses
and thousands of golfers.
Raising Money
and Awareness
Boxing champion and Olympic gold
medalist Sugar Ray Leonard joined fashion
designer Pamela Dennis and other celebrities
at the PCF Shadow Creek Invitational golf
tournament fund-raising event.
Ha ll of Fame hockey legend Wayne Gret z k y
participated at the PCF Champions
Challenge for a Cure Run/Walk at the
Staples Center in Los Angeles.The annual
walk and interactive sports festival is a
family event that increases awareness of the
effects of prostate cancer on men and their
families,and raises money to increase cancer
research funding.
Talk show host Larry King joined Whoopi
Goldberg,mistress of ceremonies at the 1998
PCF New York Dinner. Larry has often
featured PCF chairman and founder Mike
Milken on his television show to discuss
prostate cancer research.
The Prostate Cancer Foundation
has supported research on the
effects of nutrition on prostate
cancer and other serious diseases.
27
Every other year, the PCF hosts a fund-
raising event at the Waldorf-Astoria Hotel
in New York to raise money for p rostate
cancer research. Past honorees Steve and
Elaine Wynn (center) receive the PCF eagle
statuette presented by Honorary PCFboard
member Robert Wagner and his wi fe ,
Ji ll St . Joh n ,( l eft) and PCF ch a i rm a n and
founder Mike Milken (right).
Named for honorary chair Arnold Palmer,
a prostate cancer survivor, the Arnie’s Army
program involves participating golf courses
s po n so ring one-day, cl o se s t - to-the-pin co n te s t s
on a preselected par-3 hole. Golfers are
encouraged to join Arnie’s Army to raise
funds and generate public awareness of
prostate cancer.
Producer/songwriter David Foster (right), a
1 4 - time Gra m my Awa rd wi n n er, and ren own ed
Australian golf legend Greg Norman provide
some en tert a i n m ent at the PCF Sh a d ow Cre e k
Invitational golf tournament to raise money
for prostate cancer research.
Nutrition
Scientists now know that prostate
cancer, like all cancers,is the result
of damage to certain genes that
regulate the growth and death of
cells. This damage is caused by a
complex, but incompletely under-
s tood ,i n teracti on bet ween hered i ty
and environment.
Di f ferent types of s c i en tific evi den ce
collectively suggest that diet and
lifestyle may account for or con-
tribute to a significant portion of
cancers, including prostate cancer.
For example,the incidence of
prostate cancer in Asian men, whose
diets have relatively small amounts
of fat and large amounts of soy
protein, is much less than that in
American men. Yet, when Japanese
men migrate to the United States
and adopt American eating habits,
their rate of prostate cancer rises to
American levels within a generation.
In addition, basic science research
on animals and cells, and clinical
trials evaluating specific nutrition
and lifestyle changes in men,show
the importance of nutrition in
preventing cancer.
From its earliest days, the Prostate
Cancer Foundation has supported
research on the effects of nutrition
on prostate cancer and other serious
diseases. And we have published
the results of those studies to pro-
vide practical guidance for patients.
The PCF has invested more than
$4 mill i on in nutri ti onal re s e a rch at
13 leading re s e a rch cen ters inclu d i n g
Harvard University, The Johns
Hopkins Un ivers i ty, M I T, Mem ori a l
Sloan-Kettering Cancer Center,
Rockefeller University, and the
U C LA Cen ter for Human Nutri ti on .
Researchers have investigated the
value of a low-fat, high-fiber diet
rich in fruits, vegetables, and grains,
as well as foods believed to contain
beneficial properties, including s oy
pro tei n , coo ked tom a to produ ct s ,
and cruciferous vegetables such
as broccoli.
The PCF has invested more than
$4 million in nutritional research
at 13 leading research centers.
28
When former New York city schools official
Harold Kobliner, Ph.D. was diagnosed with
prostate cancer, he and his family searched
for answers.The PCF’s nutrition project
presented an alternative therapy supported
by ongoing scientific research.
Nutrition and Prostate Cancer: A
Monograph from the PCF Nutrition
Project gives prostate cancer patients nutri-
tional approaches to fighting the disease.
Although the evidence provides few
absolute truths, studies show that:
• Men who eat more cooked tomato
products had fewer cases of prostate
cancer. Lycopene, a powerful antiox-
idant, is released and becomes more
bioavailable when tomatoes are
heated. It may inhibit processes in
the body that lead to cancer.
• A low-fat,high-fiber diet rich in
fruits, vegetables, soy, and grains
may halt, or even reverse,the
growth of prostate cancer.
• Men who consume large quantities
of red meat and dairy products may
increase their risk of prostate cancer.
• Being overweight increases the
risk of virtually every cancer. An
American Cancer Society study
showed that overweight men were
52% more likely to die from cancer
than men of normal weight.
To help men understand these and
other findings and adopt healthier
lifestyles,the Prostate Cancer
Foundation has published two
cookbooks, The Taste for Living
Cookbook, and The Taste for Living
WORLD Cookbook. Both contain
great-tasting, thoroughly tested,
easy-to-prepare recipes. We have
also published the fourth edition
of the monograph Nutrition and
Pro s t a te Cancer, wh i ch de s c ri bes the
current state of nutrition research.
Both cookbooks and the mono-
graph are available on our web site:
www.prostatecancerfoundation.org.
Raising Money
and Awareness
Men who eat more cooked tomato products
had fewer cases of prostate cancer. Lycopene,
a powerful antioxidant,is released and
becomes more bioavailable when tomatoes
are heated. It may inhibit processes in the
body that lead to cancer.
29
We didn’t get to these people in time.
We can and must do more. The need remains great.
Your help has never been more important.
Timothy Leary 1920-1996
Telly Savales 1924-1994Steve Ross 1927-1993
Francois Mitterand 1916-1996
Linus Pauling, Ph.D. 1901-1994Jay Chiat 1934-2002
Bill Bixby 1934-1993
Frank Zappa 1941-1993
30
Professor Gerald Haslam
Diagnosed with prostate
cancer at age 60.
When author and professor Gerald
Haslam retired after 30 years at
Ca l i fornia State Un ivers i ty, l i fe wasn’t
what he expected. Just months after
undergoing prostate surgery and
radiation treatment, the news from
one of his follow-up visits was
devastating: his PSA level was on
the rise. His physician feared that
his cancer had retu rn ed and referred
him to the University of California,
San Francisco (UCSF), a leading
cancer center and one of eight
members of the Prostate Cancer
Foundation Therapy Consortium.
Dr. Eric Small, an oncologist,
enrolled Mr. Haslam in a PCF-
funded clinical trial of an innovative
form of immunotherapy that stimu-
lates the body’s immune system
to eradicate prostate cancer cells.
Immunotherapy is similar in theory
to receiving a vaccine or flu shot.
Compared to other treatments for
prostate cancer, immunotherapy has
proven to be relatively nontoxic.
“I’d always planned to retire at 60,”
Professor Haslam says,“just not
under these circumstances. I was
a lw ays an athlete and sti ll con s i dered
myself young and alive.”
“The best patient care always comes
from integrating the most innova-
tive and novel therapeutics with a
vigorous research program,” says Dr.
Small. “Without the PCF’s financial
support of UCSF’s immunotherapy
research, Mr. Haslam’s treatment
options would have been limited.
Our participation in the Prostate
Cancer Foundation Therapy
Consortium has helped transform
us into a top-tier cancer center.
We strengthened our research
infrastructure to complement the
expertise we already had.”
• One in six men will get prostate
cancer in their lifetimes.
• Every 2 1/2 minutes a man is
diagnosed with prostate cancer.
• Ever 18 minutes, a man dies
from prostate cancer in the
United States.
Dr. Small’s colleague,urologist
Peter Carroll,agrees. “The PCF
gave us not only the impetus, but
the guidance to become better. As
a result, we have been able to help
many more patients with high-risk
prostate cancer.”
Today, Mr. Haslam’s PSA is down
to an acceptable level. He continues
his fight against prostate cancer and
expects to enter another clinical trial
involving the hereditary factors of
the disease. Because his family has
a history of prostate cancer, he and
his three sons are also participating
in a PCF-funded study of familial
predisposition for prostate cancer.
“Wh en I do die, my death wi ll have
been of value in the long-term
struggle. And if something I experi-
ence helps my sons down the road,
that’s a wonderful gift. Hope in any
form is priceless,” says Mr. Haslam.
Gerald Haslam continues his fight against
prostate cancer and expects to enter another
clinical trial involving the hereditary factors
of the disease. Because his family has a his-
tory of prostate cancer, he and his three sons
are also participating in a PCF-funded study
of familial predisposition for prostate cancer.
Patient Profile
“ I ’d alw ays planned to reti re at 60, just not under
these circ u m s t a n ce s .”
32
Research Awards
2002 David H. Koch Aw a r d s
This year the Prostate Cancer
Foundation launched the David
H. Koch Awards. Mr. Koch’s
extraordinary generosity enabled
the PCF to provide more than
$3 million to fund major research
programs at:
• The Johns Hopkins University
• M. D. Anderson Cancer Center
• Memorial Sloan-Kettering
Cancer Center
Albert Einstein College of Medicine
$75,000
Nicole B. Schreiber-Agus,Ph.D.
Assaf Harofe Medical Center (Israel)
$150,000
Amnon Zisman,M.D.
Bar-Ilan University (Israel)
$225,000
Shlomo Grossman,Ph.D.
Uri Nir, Ph.D.
Baylor University
$3,200,000
Jacques Banchereau,Ph.D.
Baylor College of Medicine
Norman M. Greenberg, Ph.D.
Dov Kadmon,M.D.
Paula Kaplan-Lefko, Ph.D.
Michael Kattan,Ph.D.
Dolores J. Lamb, Ph.D.
Bert W. O’Malley, M.D.
David R. Rowley, Ph.D.
Peter T. Scardino, M.D.
Timothy C. Thompson,Ph.D.
Ming-Jer Tsai,Ph.D.
Nancy L. Weigel,Ph.D.
Ben-Gurion University
of the Negev (Israel)
$375,000
Ron N. Apte,Ph.D.
Joseph Levy, Ph.D.
Angel Porgador, Ph.D.
Shraga Segal,Ph.D.
Brandeis University
$250,000
Lizbeth Hedstrom,Ph.D.
Gregory A. Petsko, Ph.D.
Burnham Institute
$1,686,000
Wadih Arap, M.D.,Ph.D.
Nuria E. Assa-Munt,Ph.D.
Kathryn R.Ely, Ph.D.
John C. Reed,M.D.,Ph.D.
Erkki I Ruoslahti,M.D.,Ph.D.
California Institute of Technology
$450,000
Raymond J. Deshaies,Ph.D.
Huatao Guo, Ph.D.
Alexander J. Varshavsky, Ph.D.
California Pacific Medical Center
$100,000
Robert J. Debs,M.D.
Cancer Institute of New Jersey
$75,000
Robert S. DiPaola,M.D.
Cantonal Hospital St.Gall
(Switzerland)
$75,000
Marcus Groettrup, Ph.D.
Case Western Reserve University
$275,000
Sanford Markowitz,M.D.,Ph.D.
Bingcheng Wang, Ph.D.
Cedars-Sinai Medical Center
$1,995,000
David B. Agus,M.D.
H.Phillip Koeffler, M.D.
Isett Laux,Ph.D.
Cleveland Clinic Foundation
$150,000
Katerina Gurova,Ph.D.
Edward Plow, Ph.D.
Cold Spring Harbor Laboratory
$100,000
Robert Lucito, Ph.D.
Columbia University
$2,129,500
Allen Pavilion Presbyterian Hospital
Carl A. Olsson,M.D.
Atchley Pavilion
Ralph Buttyan,Ph.D.
College of Physicians and Surgeons
Paul B. Fisher, Ph.D.
Aaron E. Katz,M.D.
Nickolas Papadopoulos,Ph.D.
Columbia Presbyterian Medical Center
Daniel Petrylak,M.D.
33
Cornell University
$4,100,000
Beatrice S. Knudsen,M.D.,Ph.D
David M. Nanus,M.D.
New York Presbyterian Hospital
Neil H. Bander, M.D.
Dartmouth-Hitchcock
Medical Center
$75,000
Marc S.Ernstoff,M.D.
Duke University
$925,000
Eli Gilboa,Ph.D.
Michael C.Pirrung, Ph.D.
David T. Price,M.D.
Johannes W. Vieweg, M.D.
Eastern Virginia Medical School
$175,000
George L. Wright Jr.,Ph.D.
Emory University
$250,000
Wayne Harris,M.D.
John A. Petros,M.D.
Erasmus University (Netherlands)
$250,000
Jan Trapman,Ph.D.
Gert J. van Steenbrugge,Ph.D.
Fred C. Hutchinson Cancer
Research Center
$2,605,000
Peter S. Nelson,M.D.
Elaine A.Ostrander, Ph.D.
Janet L.Stanford,Ph.D.
Georgetown University
$1,000,000
Lombardi Cancer Center
Edward P. Gelmann,M.D.
Robert L. Martuza,M.D.
Renxiao Wang, Ph.D.
Shaomeng Wang, Ph.D.
Hadassah University (Israel)
$425,000
Rachel Bar-Shavit,Ph.D.
Eithan Galun,M.D.,Ph.D.
Amnon Peled,Ph.D.
Eli Pikarsky, M.D.,Ph.D.
Israel Vlodavsky, Ph.D.
Harvard University
$10,625,000
Beth Israel Deaconess Medical Center
Lewis C. Cantley, Ph.D.
John V. Fragioni,M.D.,Ph.D.
Sandra M.Gaston,Ph.D.
Towia A.Libermann,Ph.D.
Massimo Loda,M.D.
Jan E.Schnitzer, M.D.
Brigham and Women’s Hospital
Anthony V. D’Amico, M.D.,Ph.D.
Phillip Febbo, M.D.
James W. Fett,Ph.D.
Joshua LaBaer, M.D.,Ph.D.
Kevin R. Loughlin,M.D.
Karen A. Olson,Ph.D.
Jeffrey L. Sklar, M.D.,Ph.D.
Children’s Hospital
Judah Folkman,M.D.
Michael Klagsburn,Ph.D.
Calvin J. Kuo, M.D.
Marsha A. Moses,Ph.D.
Richard C. Mulligan,Ph.D.
Bruce R. Zetter, Ph.D.
Dana-Farber Cancer Institute
Ranaan Berger, M.D.,Ph.D.
Myles A. Brown,M.D.
Harvey Cantor, M.D.
Diego Castrillon,M.D.,Ph.D
Lan Bo Chen,Ph.D.
Glenn Dranoff,M.D.
Daniel J. George,M.D.
William C. Hahn,M.D.,Ph.D.
Philip W. Kantoff,M.D.
David M.Livingston,M.D.
Massimo Loda,M.D.
Thomas Roberts,Ph.D.
William R. Sellers,M.D.
Sabina Signoretti,M.D.
Bruce M.Spiegelman,Ph.D.
Robert H. Vonderheide,M.D., D.Phil.
Harvard School of Public Health
June M. Chan,Sc.D.
Edward Giovannucci,M.D.
Laurie H.Glimcher, M.D.
Dimitrios Trichopoulos,M.D.
Massachusetts General Hospital
Joel Finkelstein,M.D.
Robert L. Martuza,M.D.
Matthew R. Smith,M.D.,Ph.D.
Ching-Hsuan Tung, Ph.D.
Anthony L. Zietman,M.D.
Hebrew University (Israel)
$800,000
Yinon Ben-Neriah,M.D.,Ph.D.
Howard Cedar, M.D.,Ph.D.
Eli Keshet,Ph.D.
Alexander Levitzki,Ph.D.
David Naor, Ph.D.
Indiana University
$200,000
Thomas A.Gardner, M.D.
George W. Sledge,M.D.
Institute for Systems Biology
$500,000
Leroy E. Hood,M.D.,Ph.D.
John Wayne Cancer Institute
$50,000
Frederick R. Singer, M.D.
Johns Hopkins University
$12,897,000
Philip A. Beachy, Ph.D.
G.Steven Bova,M.D.
Michael A. Carducci,M.D.
Angelo DeMarzo, M.D.,Ph.D.
Samuel R. Denmeade,M.D.
Mario Eisenberger, M.D.
John T. Isaacs,Ph.D.
William B. Isaacs,Ph.D.
Hyam I. Levitsky, M.D.
Joel B. Nelson,M.D.
William G. Nelson,M.D.,Ph.D.
Alan W. Partin,M.D.,Ph.D.
Ronald Rodriguez,M.D.,Ph.D.
Jonathan W. Simons,M.D.
Patrick C. Walsh,M.D.
34
Karolinska Institute (Sweden)
$75,000
Hans-Olov Adami,M.D.,Ph.D.
Klinikum de Justus-Liebig
Universitat Giessen (Germany)
$175,000
Trinad Chakraborty
La Jolla Institute for
Allergy and Immunology
$75,000
Stephen Schoenberger, Ph.D.
Long Island College Hospital
$15,000
Ivan Grunberger, M.D.
Loyola University Medical Center
$200,000
Eugene D. Kwon,M.D.
McGill University
$75,000
Nahum Sonenberg, Ph.D.
Massachusetts Institute
of Technology
$1,535,000
Sandra M.Gaston,Ph.D.
Richard O. Hynes,Ph.D.
Jun Liu,Ph.D.
Peter H. Seeberger, Ph.D.
Ganesh Venkataraman,Ph.D.
Whitehead Institute for
Biomedical Research
John M.Essigmann,Ph.D.
Eric S.Lander, Ph.D.
Richard C. Mulligan,Ph.D.
Mayo Clinic and Foundation
$500,000
Lorraine A.Fitzpatrick,M.D.
John C. Morris,M.D.
Donald J. Tindall,Ph.D.
Memorial Sloan-Kettering
Cancer Center
$14,060,000
David B. Agus,M.D.
William R. Fair, M.D., F.A.C.S.
George Farmer, Ph.D.
Leonard P. Freedman,Ph.D.
Zvi Fuks,M.D.
Polly Gregor, Ph.D.
Adriana Haimovitz-Friedman,Ph.D.
Warren D.W. Heston,Ph.D.
William Kevin Kelly, M.D.
Philip O. Livingston,M.D.
Paul A. Marks,M.D.
Michael R. McDevitt,Ph.D.
David Nanus,M.D.
Neal Rosen,M.D.,Ph.D.
Michael Sadelain,M.D.,Ph.D.
Peter T. Scardino, M.D.
David A.Scheinberg, M.D.,Ph.D.
Howard I.Scher, M.D
George Sgouros, Ph.D.
David Shaffer, M.D.,Ph.D.
Moshe Shike, M.D.
Susan F. Slovin,M.D.,Ph.D.
Peter Smith-Jones,Ph.D.
Jedd D. Wolchok,M.D.,Ph.D.
Menzies Centre for Population
Health Research (Australia)
$50,000
David A. Mackey, M.D.
Mount Sinai School of Medicine
$275,000
Michael J. Droller, M.D.
Irwin H.Gelman,Ph.D.
John A. Martignetti,M.D.,Ph.D.
New York Medical College
$150,000
Cancer Research Institute
Sophie Chen,Ph.D.
New York University
$430,000
Maarten C. Bosland, D.V.Sc.,Ph.D.
Herbert Lepor, M.D.
Ian J. Mohr, Ph.D.
Samir Taneja,M.D.
Skirball Institute of
Biomolecular Medicine
Ruben Abagyan,Ph.D.
Northwest Hospital
$475,000
Gerald P. Murphy, M.D., D.Sc.
Research Awards
35
Northwestern University
$200,000
Wade Bushman,M.D.,Ph.D.
Zhou Wang, Ph.D.
Ohio State University
$100,000
M. Guill Wientjes Ph.D.
Oregon Health Sciences University
$100,000
Ron G. Rosenfeld,M.D.
Preventive Medicine Research
Institute
$500,000
Dean Ornish,M.D.
Rabin Medical Center (Israel)
$50,000
Avishay Sella,M.D.
Rockefeller University
$500,000
Robert G. Roeder, Ph.D.
Strang Cancer Research Laboratory
Martin Lipkin,M.D.
Salk Institute for Biological Studies
$760,050
Ronald M. Evans,Ph.D.
San Diego Cancer Research
$75,000
R. Michael Williams,M.D.,Ph.D.
Scripps Research Institute
$975,000
Ruben A. Abagyan,Ph.D.
K.C. Nicolaou,Ph.D.
Prabhakar Tripuraneni,M.D.
Sheba Medical Center (Israel)
$150,000
Gideon Rechavi,M.D.,Ph.D.
Stanford University
$1,225,000
Gerald R. Crabtree,M.D.
David Feldman,M.D.
Calvin J. Kuo, M.D.
John E. McNeal,M.D.
Donna M. Peehl,Ph.D.
Thomas A.Stamey, M.D.
St.Louis University
$75,000
William S.M. Wold,Ph.D.
State University of New York
$112,500
Downstate Medical School
Jack Mydlo, M.D.
Stony Brook
Victor I. Romanov, Ph.D.
Technion, Israel Institute of
Technology (Israel)
$625,000
Ami Aronheim,Ph.D.
Aaron Ciechanover, M.D., D.Sc.
Fuad Fares, D.Sc.
Ehud Keinan,Ph.D.
Gera Neufeld,Ph.D.
Israel Vlodavsky, Ph.D.
Tel-Aviv University (Israel)
$400,000
Zvi Fishelson,Ph.D.
Sara Lavi,Ph.D.
Ada Rephaeli,Ph.D.
Ilan Tsarfaty, Ph.D.
Sourasky Medical Center
Ben-Zion Katz,Ph.D.
Avi Orr-Urtreger, M.D.,Ph.D.
Thomas Jefferson University
$125,000
Michael J. Mastrangelo, M.D.
Albert J. Wong, M.D.
Tulane University
$500,000
Andrew V. Schally, M.D.,Ph.D.
University Hospital,
Nijmegen (Netherlands)
$275,000
Marion J.G. Bussemakers,Ph.D.
University of Alabama, Birmingham
$100,000
David T. Curiel,M.D.
University of Arizona
$150,000
Leslie Gunatilaka,Ph.D., B.S.
Mark W. Kunkel,Ph.D.
University of Basel (Switzerland)
$75,000
Lukas Bubendorf,M.D.
University of Bern (Switzerland)
$100,000
George N. Thalmann,M.D.
University of California
$15,990,068
Lawrence Livermore
National Laboratory
Christine Hartmann Siantar, Ph.D.
University of California, Berkeley
James P. Allison,Ph.D.
Carolyn Bertozzi,Ph.D.
Arthur A. Hurwitz,Ph.D.
David H. Raulet,Ph.D., B.S.
Peter G.Schultz,Ph.D.
David E. Wemmer, Ph.D.
University of California, Davis
Shing-Jien Kung, Ph.D.
University of California, Los Angeles
Arie S. Belldegrun,M.D.
Michael F. Carey, Ph.D.
Rowan T. Chlebowski,M.D.,Ph.D.
Pinchas Cohen,M.D.
Jean B. deKernion,M.D.
Purnima Dubey, Ph.D.
Sanjiv S.Gambhir, M.D.,Ph.D.
David Heber, M.D.,Ph.D.
Harvey R. Herschman,Ph.D.
Jay R.Lieberman,M.D.
Carl W. Miller, Ph.D.
Ayyappan K. Rajasekaran,Ph.D.
Robert Reiter, M.D.
Peter Rosen,M.D.
Marc A. Seltzer, M.D.
Kathleen M. Sakamoto, M.D.
Charles L. Sawyers,M.D
Marc A. Seltzer, M.D.
Ke Shuai,Ph.D.
Peter Tontonoz,M.D.,Ph.D.
Owen N. Witte,M.D.
Hong Wu,M.D.,Ph.D.
36
University of California,San Diego
Dennis A. Carson,M.D.
Randolph D. Christen,M.D.
Lawrence S.B. Goldstein,Ph.D.
Michael G. Rosenfeld,Ph.D.
Helen P. Tighe,Ph.D.
Maurizio Zanetti,M.D.
University of California,San Francisco
Jeffrey Arbeit,M.D.
Allan Balmain,Ph.D.
Elizabeth Blackburn,Ph.D.
Peter R. Carroll,M.D.
June Chan,Sc.D.
Robert Fletterick,Ph.D.
Mark W. Frohlich,M.D.
Douglas Hanahan,Ph.D.
Ronald H. Jensen,Ph.D.
John Kurhanewicz,Ph.D.
James D. Marks,M.D.,Ph.D.
Dean Ornish,M.D.
Mack Roach,III,M.D.
Eric J. Small,M.D.
Thea Tlsty, Ph.D.
University of California,Santa Barbara
Dulal Panda,Ph.D.
University of Chicago
$425,000
Douglas K. Bishop, Ph.D.
Carrie W. Rinker-Schaeffer, Ph.D.
Mitchell H. Sokoloff,M.D.
Ben May Institute for Cancer Research
Shutsung Liao, Ph.D.
University of Colorado
$655,000
L. Michael Glode,M.D.
William E. Huffer, M.D.
Andrew S. Kraft,M.D.
Gary J. Miller, M.D., Ph.D.
University of Connecticut
$100,000
Pramod Srivastava,Ph.D.
University of Edinburgh (Scotland)
$75,000
Fouad K. Habib, Ph.D.
University of Helsinki (Finland)
$200,000
Institute of Biomedicine
Olli A. Janne,M.D.,Ph.D.
University of Illinois
$50,000
Nissum Hay, Ph.D.
University of Innsbruck (Austria)
$100,000
Zoran Culig, M.D.
University of Iowa
$75,000
George Weiner, M.D.
University of Kentucky
$100,000
Vivek M. Rangnekar, Ph.D.
University of Maryland
$100,000
Natasha Kyprianou,Ph.D.
University of Massachusetts
$325,000
Michael R. Green,M.D.,Ph.D.
Shuk-Mei Ho, Ph.D.
Mani Menon,M.D.
University of Michigan
$3,000,000
Arul M. Chinnaiyan,M.D.,Ph.D.
Mark Day, Ph.D.
Evan T. Keller, D.V.M.,Ph.D.
Donna Livant,Ph.D.
Kenneth J. Pienta,M.D.
Martin G. Sanda,M.D.
Shaomeng Wang, Ph.D.
University of Munich (Germany)
$100,000
Bernd Gansbacher, M.D.
University of Nebraska
$100,000
Ming-Fong Lin,Ph.D.
University of North Carolina,
Chapel Hill
$150,000
David Ornstein,M.D.
University of Pennsylvania
$400,000
Mark I. Greene, M.D.,Ph.D.
Research Awards
37
Wistar Institute
George C. Prendergast,Ph.D.
University of Pittsburgh
$2,275,000
Michael J. Becich,M.D.,Ph.D
Barbara A. Foster, Ph.D
John Gilbertson,M.D.
Susan L. Greenspan,M.D.
Candace S. Johnson,Ph.D.
Joel B. Nelson,M.D.
Donald L. Trump, M.D.
Janey Whalen,Ph.D.
University of Rochester
$400,000
Chawnshang Chang, Ph.D.
Edward Messing, M.D.
University of Southern California
$100,000
Donald G. Skinner, M.D.
University of Tampere (Finland)
$300,000
Tapio Visakorpi,M.D.,Ph.D.
University of Tennessee
$150,000
Jeffrey Gingrich,M.D.
University of Texas
$10,917,000
Health Science Center at San Antonio
Susan Padalecki,Ph.D.
The M.D. Anderson Cancer Center
Wadih Arap, M.D.,Ph.D.
Danai Daliani,M.D.
John DiGiovanni,Ph.D.
Isaiah J. Fidler, D.V.M.,Ph.D.
Sue-Hwa Lin,Ph.D.
Christopher J. Logothetis,M.D.
David J. McConkey, Ph.D.
Timothy J. McDonnell,M.D.,Ph.D.
Nora M. Navone,M.D.,Ph.D.
Christos N. Papandreou,M.D.,Ph.D.
Andrew C. von Eschenbach,M.D.
Christopher G. Wood,M.D.
Southwestern Medical Center, Dallas
Jerry W. Shay, Ph.D.
University of Toronto (Canada)
$350,000
Sunnybrook Health Science Center
Shoukat Dedhar, Ph.D.
Robert S. Kerbel,Ph.D.
University of Utah, Health
Sciences Center
$100,000
Arthur R. Brothman,Ph.D.
University of Virginia
$3,650,000
Leland W.K. Chung, Ph.D.
Thomas A.Gardner, M.D.
Deborah Lannigan,Ph.D.
Charles E. Myers,Jr.,M.D.
J. Thomas Parsons,Ph.D.
Fraydoon Rastinejad,Ph.D.
Mitchell Sokoloff,M.D.
Michael J. Weber, Ph.D.
University of Washington
$7,873,220
Arthur Camerman,Ph.D.
Martin A. Cheever, M.D.
Leroy Hood,M.D.,Ph.D.
Gail Jarvik,M.D.,Ph.D.
Paul H.Lange,M.D.
Alvin Liu,Ph.D.
Robert L. Vessella,Ph.D.
University of Wisconsin
$3,875,000
David A. Boothman,Ph.D.
Chawnshang Chang, Ph.D.
David F. Jarrard,M.D.
Douglas G. McNeel,M.D.,Ph.D.
George Wilding, M.D.
Donald T. Witiak,Ph.D.
Urological Sciences
Research Foundation
$100,000
Leonard S. Marks,M.D.
Utah State Cancer Registry
$183,420
Janet Stanford,M.D.
Vanderbilt University
$350,000
Sam Chang, M.D.
Robert Matusik,Ph.D.
Joseph A. Smith,Jr.,M.D.
Veteran’s Administration
$4,622
Patricia Cornett,M.D.
Volcani Center (Israel)
$180,000
Mark Pines,Ph.D.
Walter Reed Army Medical Center
$50,000
David G. McLeod,M.D., J.D.
Washington University
$3,339,166
William J. Catalona,M.D.
Mark L.Day, Ph.D.
Helen Donis-Keller, Ph.D.
Steven F. Dowdy, Ph.D.
Peter A. Humphrey, M.D.,Ph.D.
Jeffrey Milbrandt,M.D.,Ph.D.
Nobuyuki Oyama, M.D.,Ph.D.
Timothy L. Ratliff,Ph.D.
Brian K. Suarez,Ph.D.
Wayne State University
$350,000
Michael L. Cher, M.D.
Keneth V. Honn,Ph.D.
Harper Hospital
J. Edson Pontes,M.D.
Weizmann Institute of Science (Israel)
$1,625,000
Avri Ben-Ze’ev, Ph.D.
Hadassa Degani,Ph.D.
Zelig Eshhar, Ph.D.
Benjamin Geiger, Ph.D.
Yitzhak Koch,Ph.D.
Yoram Salomon,Ph.D.
Rony Seger, Ph.D.
Yechiel Shai,Ph.D
Yosef Shaul,Ph.D.
David Wallach,Ph.D.
Yosef Yarden,Ph.D.
Yehiel Zick,Ph.D.
Yale University
$200,000
Craig M. Crews,Ph.D.
38
Gerald Ford
Jimmy Carter
Ronald Reagan
George H. W. Bush
Bill Clinton
Presidential Board Board of Directors
Michael Milken
Chairman
Prostate Cancer Foundation
Merv Adelson
Chairman
East West Venture Group
James Blair
General Partner
Domain Associates
Helene Brown
Director Community
Applications of Research
University of California,
Los Angeles
S. Ward (Trip) Casscells III,M.D.
John Edward Tyson
Distinguished Professor of
Medicine and Vice President
of Biotechnology
University of Texas HSC
at Houston
David Ederer
Chairman
Ederer Investment Company
Sue Gin
Chairman and Chief
Executive Officer
Flying Food Group, Inc.
The Reverend Rosey Grier
Milken Family Foundation
Andrew Grove
Chairman
Intel Corporation
Stuart Holden,M.D.
Director
Cedars-Sinai Louis
Warschaw Prostate Cancer Center
Warschaw, Robertson, Law Families
Chair in Prostate Cancer
Cedars-Sinai Medical Center
David Koch
Executive Vice President
Koch Industries
Earle Mack
Senior Partner
The Mack Company
Shmuel Meiter
Director
Aurec Group
Lori Milken
Vice President
Prostate Cancer Foundation
Nelson Peltz
Chairman and Chief
Executive Officer
Triarc Companies, Inc.
Lynda Resnick
Vice Chairman
Roll International
Bert Roberts
Consultant
Richard Sandler
Partner, Maron and Sandler
Executive Vice President
Milken Family Foundation
Lorraine Spurge
Managing Director
Metropolitan West Financial
Michael L. Tarnopol
Vice Chairman
Bear, Stearns & Co. Inc.
Robert Voss
President
Fox Packaging Company
Jerry Weintraub
President
Jerry Weintraub Productions
Elaine Wynn
Co-Chief Executive Officer
Wynn Resorts
Stanley Zax
Chairman and President
Zenith National Insurance Corporation
Leadership
39
Executive Officers
Leslie D. Michelson
Vice Chairman and
Chief Executive Officer
Debbie Bohnett
Executive Vice President,
Marketing and Development
Howard Soule, Ph.D.
Executive Vice President
and Chief Science Officer
Stuart Holden,M.D.
Chief Medical Officer
Michael B. Kaiserman
Chief Development Officer
Gregg S. Britt
Senior Vice President,
Biopharmaceutical Research
and Development
Scott Harvey
Senior Vice President,
Corporate Alliances
Jan Haber
Manager, Special Events
Honorary Board
Ken Aretsky
Edward Asner
Anne Bancroft
Warren Beatty
Harry Belafonte
Samuel Belzberg
Metuka Benjamin
Fred Biletnikoff
Pat Boone
Mel Brooks
John S. Chalsty
Tony Coelho
Jim Colbert
Bill Cosby
Jamie B. Coulter
Billy Davis,Jr.
Alan Dershowitz
Sen. Robert Dole
Clint Eastwood
Sen. Dianne Feinstein
Irving Feintech
David Foster
Emil Frei III,M.D.
Howard Gittis
Whoopi Goldberg
Berry Gordy
Robert Goulet
General Alexander Haig
Monty Hall
Alan Hassenfeld
Quincy Jones
Hamilton Jordan
Joseph Kanter
Neal Kassell,M.D.
Sidney Kimmel
Larry King
John W. Kluge
Beth Kobliner
Sandy Koufax
Tommy Lasorda
Tom Laughlin
Norman Lear
Marv Levy
Carl Lindner
Robert Linton
Marilyn McCoo
Lowell Milken
Avram Miller
Jerry Monkarsh
Robert Novak
Arnold Palmer
Claudia Peltz
Sidney Poitier
Charlie Rose
Gen.H. Norman Schwarzkopf
Marvin Shanken
Sen. Brad Sherman
Neil Simon
Sen. Ted Stevens
Louis W. Sullivan,M.D.
Allan Tessler
William H. Tilley
Joe Torre
Clyde Turner
Tracey Ullman
Robert Wagner
Rep. Maxine Waters
Bob Watson
Will Weinstein
Jerry West
Stephen Wynn
Bud Yorkin
40
We Need You
The Prostate Cancer Foundation
welcomes your help and support in
our mission to find better treat-
ments and a cure for adva n ced
pro s t a te cancer.
Three Ways to Donate
Please mail your check to:
Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, California 90401
Make your check payable to
the Prostate Cancer Foundation.
To make an online contribution,
please visit our web site:
www.prostatecancerfoundation.org
To make a credit card donation call
8 0 0 . 7 5 7 . 2 8 7 3 .
Memorial or Tribute Gifts
Honor the memory of a loved one
or celebrate the accomplishment
of a friend or family member by
helping others. Make a memorial or
tribute gift and the PCF will send an
acknowledgement card to the family
of the honoree.
The Pro s t a te Ca n cer Fo u n d a ti on• Funds innova tive re s e a rch that leads to bet ter tre a tm en t s .
• Puts money in researchers’ hands quickly.
• Brings together leading academic scientists with biotech
and pharmaceutical companies and government leaders
and researchers.
• Su pports a con s ortium of the nati on’s leading cancer cen ters .
• Leads public awareness campaigns about prostate cancer.
• Gives men and their families hope for better, longer lives.
Other Gift Suggestions
• Assets or property including
real estate.
• Bequest — include a gift to PCF
in your will.
• Securities.
• Name the PCF as the primary or
contingent beneficiary on a life
insurance policy.
We will be happy to work with you
and your advisors to arrange a gift
that meets the needs of you and
your family. Thank you for your
generous support.
For additional information,please
c a ll us at 800.757.2873 or e-mail us at
The chart on page 6 inc ludes the most recently reported annual results for the following philanthropies: Alzheimer’s and
Related Disorders Association, American Cancer Society, American Foundation for AIDS Research, American Heart Association,
American Lung Association, Arthritis Foundation, Christopher Reeve Paralysis Foundation, Juvenile Diabetes Research
Foundation, Leukemia and Lymphoma Foundation, March of Dimes, Muscular Dystrophy Association, National Kidney
Foundation, National Multiple Sclerosis Society and Susan G. Komen Breast Cancer Foundation.
1250 Fourth Street
Santa Monica, California 90401
Tel 310.570.4700 Fax 310.570.4701
www.prostatecancerfoundation.org